title: Digoxin is a selective modifier increasing platinum drug anticancer activity.
abstract: Using the model of breast cancer Ehrlich ascites tumor in mice, we showed that a sigle intraperitoneal injection of cardiac glycoside digoxin 1 h before the intraperitoneal injection of cisplatin increased the anticancer effect of the cytostatic drug more than twice when recalculated for the dose. It is assumed that the modifying effect of digoxin is determined by the direct inhibition of glycolysis in tumor cells. Taking into account the design of the study, we consider promising the clinical evaluation of the effectiveness of digoxin as a modifier of cisplatin efficiency in intracavitary therapy of ascites cancers with pleural and abdominal dissenmination.
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia. tatbogush@mail.ru.
authors.forename: T A
authors.initials: TA
authors.lastname: Bogush
authors.affiliation: Faculty of Biology, Lomonosov Moscow State University, Moscow, 119991, Russia.
authors.forename: V Yu
authors.initials: VY
authors.lastname: Chernov
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia.
authors.forename: E A
authors.initials: EA
authors.lastname: Dudko
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia.
authors.forename: Z S
authors.initials: ZS
authors.lastname: Shprakh
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia.
authors.forename: E A
authors.initials: EA
authors.lastname: Bogush
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia.
authors.forename: B E
authors.initials: BE
authors.lastname: Polotsky
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia.
authors.forename: S A
authors.initials: SA
authors.lastname: Tjulandin
authors.affiliation: N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Kashirskoe sh. 24, Moscow, 115478, Russia.
authors.forename: M I
authors.initials: MI
authors.lastname: Davydov
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology*; D004077:Digoxin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006019:Glycolysis / Q000187:drug effects; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004077:Digoxin; D002945:Cisplatin